Skip to main content

. 1984 Apr;17(4):485–486. doi: 10.1111/j.1365-2125.1984.tb02378.x

The effect of spironolactone on the liver microsomal enzyme system in patients.

E E Ohnhaus, E Gerber-Taras

PMCID: PMC1463394 PMID: 6144319

485

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Feller D. R., Gerald M. C. Interactions of spironolactone with hepatic microsomal drug-metabolizing enzyme systems. Biochem Pharmacol. 1971 Aug;20(8):1991–2000. doi: 10.1016/0006-2952(71)90398-4. [DOI] [PubMed] [Google Scholar]
Huffman D. H., Shoeman D. W., Pentikäinen P., Azarnoff D. L. The effect of spironolactone on antipyrine metabolism in man. Pharmacology. 1973;10(6):338–344. doi: 10.1159/000136455. [DOI] [PubMed] [Google Scholar]
Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
Talcott R. E., Stohs S. J. Metabolism of aniline and hexobarbital by liver homogenates of spironolactone-pretreated male rats. J Pharm Sci. 1972 Feb;61(2):296–297. doi: 10.1002/jps.2600610240. [DOI] [PubMed] [Google Scholar]
Taylor S. A., Rawlins M. D., Smith S. E. Spironolactone--a weak enzyme inducer in man. J Pharm Pharmacol. 1972 Jul;24(7):578–579. doi: 10.1111/j.2042-7158.1972.tb09061.x. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES